MDLN
LONGINSIDER BUYINSIDER SELLMEDLINE INC
Research: Finviz ↗·Perplexity ↗
🗄 Viewing archived Q1 2026 data — frozen, no longer refreshed.
News Summary
NegativeMedline delivered strong revenue growth (11.1% YTD) and beat EPS estimates, but reported a 42% decline in net income and significantly cut Adjusted EBITDA guidance due to tariffs, inflationary pressures, and operational challenges. The company faces compounding regulatory headwinds including two FDA warning letters, product recalls affecting 970+ lots, and securities investigations that create material legal and reputational risk.
Red flags
- •Net income declined 42.3% YTD despite 11.1% revenue growth, indicating severe margin compression
- •Adjusted EBITDA guidance cut from $3.5-3.6B to $3.3-3.4B ($200-300M reduction) due to tariffs, inflation, and operational issues
- •Two FDA warning letters within two months (May 28 and June 9, 2026) citing manufacturing violations and microbial contamination
- •Product recall affecting 970+ convenience kit lots due to potential contamination with serious health risks
- •Multiple securities investigations announced by law firms regarding potential violations related to FDA warning letter
- •COO retirement (August 30, 2026) cited for health reasons, creating leadership transition during regulatory crisis
- •Quality remediation efforts ongoing with costs impacting profitability
- •Retail channel softness noted as additional headwind
Funds Buying (4)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Lone Pine Capital | Steve Mandel | 11.8M | +73K | $525M | 4.2% | +1% | Existing |
| Viking Global | Andreas Halvorsen | 11.4M | +4.5M | $509M | 1.4% | +64% | Existing |
| Durable Capital Partners | Henry Ellenbogen | 7.3M | +366K | $323M | 3.3% | +5% | Existing |
| Point72 | Steve Cohen | 3.3M | +3.3M | $147M | 0.3% | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.
Portfolio Context
Where MDLN ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.
position #8 of this fund's book
- 5QNITY ELECTRONICS INC$587M
- 6XPO INC$571M
- 7FERGUSON ENTERPRISES INC$511M
- 8MEDLINE INC$323M
- 9CARVANA CO$313M
- 10CLEAN HARBORS INC$301M
- 11UL SOLUTIONS INC$282M
position #10 of this fund's book
- 7TERADYNE INC$555M
- 8CARVANA CO$552M
- 9NU HLDGS LTD$546M
- 10MEDLINE INC$525M
- 11CORNING INC$506M
- 12CLEAN HARBORS INC$503M
- 13MASTEC INC$493M
position #29 of this fund's book
- 26REGAL REXNORD CORPORATION$589M
- 27MID-AMER APT CMNTYS INC$586M
- 28JOHNSON CONTROLS INTERNATION$579M
- 29MEDLINE INC$509M
- 30HCA HEALTHCARE INC$509M
- 31ATI INC$485M
- 32CELESTICA INC$466M
Values are quarter-end position sizes. Shown only for funds where MDLN ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.
Signal History
| Quarter | Direction | Funds | Score | vs SPY |
|---|---|---|---|---|
| Q2 2026 | SHORT | 3 | 3.11 | -19.5% |
| Q1 2026 | LONG | 4 | 4.85 | -39.4% |
Same issuer appearing in consecutive quarters — persistent institutional conviction. Returns are frozen at each archived quarter's last refresh.
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| GIC Private Ltd | — | SELL | 590K | $35.58 | $21.00M | 2026-08-07 | ↗ |
| GIC Private Ltd | — | SELL | 272K | $35.33 | $9.61M | 2026-08-06 | ↗ |
| GIC Private Ltd | — | SELL | 266K | $36.48 | $9.69M | 2026-08-05 | ↗ |
| GIC Private Ltd | — | SELL | 1.7M | $35.46 | $60.67M | 2026-08-05 | ↗ |
| Golwas Douglas P | Chief Commercial Officer | SELL | 62K | $36.60 | $2.27M | 2026-06-16 | ↗ |
| Golwas Douglas P | Chief Commercial Officer | SELL | 38K | $37.05 | $1.41M | 2026-06-16 | ↗ |
| CORCORAN JESSI L | Principal Accounting Officer | BUY | 5K | $34.15 | $0.17M | 2026-06-05 | ↗ |
| BCP 8 Holdings Mozart Manager L.L.C. | — | SELL | 2.3M | $36.54 | $82.46M | 2026-05-28 | ↗ |
| BCP 8 Holdings Mozart Manager L.L.C. | — | SELL | 1.5M | $36.54 | $54.44M | 2026-05-28 | ↗ |
| BX Mozart ML-2 Holdco L.P. | — | SELL | 19.7M | $36.54 | $720.24M | 2026-05-28 | ↗ |
| BX Mozart ML-2 Holdco L.P. | — | SELL | 9.9M | $36.54 | $360.21M | 2026-05-28 | ↗ |
| BX Mozart ML-2 Holdco L.P. | — | SELL | 2.3M | $36.54 | $82.46M | 2026-05-28 | ↗ |
| BX Mozart ML-2 Holdco L.P. | — | SELL | 1.5M | $36.54 | $54.44M | 2026-05-28 | ↗ |
| Hellman & Friedman Capital Partners X (Parallel), L.P. | — | SELL | 17.9M | $36.54 | $655.75M | 2026-05-28 | ↗ |
| Hellman & Friedman Capital Partners X (Parallel), L.P. | — | SELL | 754K | $36.54 | $27.53M | 2026-05-28 | ↗ |
| Hellman & Friedman Capital Partners X (Parallel), L.P. | — | SELL | 11.9M | $36.54 | $434.97M | 2026-05-28 | ↗ |
| Hellman & Friedman Capital Partners X (Parallel), L.P. | — | SELL | 1.3M | $36.54 | $46.14M | 2026-05-28 | ↗ |
| BCP 8 Holdings Mozart Manager L.L.C. | — | SELL | 19.7M | $36.54 | $720.24M | 2026-05-28 | ↗ |
| BCP 8 Holdings Mozart Manager L.L.C. | — | SELL | 9.9M | $36.54 | $360.21M | 2026-05-28 | ↗ |
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| Hellman & Friedman Capital Partners X (Parallel), L.P. | SC 13G | 85.7M | 9.2% | 2026-02-13 | ↗ |
| Carlyle Group Inc. | SC 13G | 215.3M | 24.4% | 2026-02-13 | ↗ |
| Mozart Aggregator II LP | SC 13G | 142.9M | 17.6% | 2026-02-13 | ↗ |
| Mozart Holdco, Inc. | SC 13G | 234.3M | 22.4% | 2026-02-13 | ↗ |
| Abu Dhabi Investment Authority | SC 13G | 47.5M | 5.9% | 2026-02-11 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.